相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients.
M. S. Barsoum et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Association Between Estrogen Receptor-β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung
Naohiro Nose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
Ignacio Duran et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Synergistic antitumor activity of the combination of the multi-targeted tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines
E. Martinelli et al.
EJC SUPPLEMENTS (2006)
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
Angela M. Davies et al.
CLINICAL LUNG CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
